Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-09-19
- Lead Sponsor
- Birte Glenthoj
- Target Recruit Count
- 46
- Registration Number
- NCT00207064
- Locations
- 🇩🇰
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup, Denmark
🇩🇰Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
🇩🇰Danish Research Center for Magnetic Resonance Imaging, Hvidovre Hospital, Hvidovre, Denmark
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 20
- Registration Number
- NCT00208143
- Locations
- 🇺🇸
Creighton University Psychiatry and Research Center, Omaha, Nebraska, United States
Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 106
- Registration Number
- NCT00182013
Treatment of Mania Symptoms With Drug Therapy
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Palo Alto Veterans Institute for Research
- Target Recruit Count
- 75
- Registration Number
- NCT00183443
- Locations
- 🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States
Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00181883
Treatment of Depression With Quetiapine
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00174603
- Locations
- 🇺🇸
Rush University Medical Center, Chicago,, Illinois, United States
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00156715
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸West Central Behavioral Health, Lebanon, New Hampshire, United States
🇺🇸Medical College of Georgia, Augusta, Georgia, United States
Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 61
- Registration Number
- NCT00124059
- Locations
- 🇺🇸
University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States
Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00113295
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
- Conditions
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 340
- Registration Number
- NCT00090012
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waco, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.